实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展

doi:10.11904/j.issn.1002-3070.2019.02.016

Abstract

Abstract: Diffuse large B-cell lymphoma(DLBCL)is a group of highly heterogeneous diseases with unique pathological characteristics and genetic changes,and the prognosis of patients depends largely on this.With the development of precision medicine,it is especially important to identify high-risk patients earlier and provides related treatments to prolong the survival time of patients and improves their quality of life.In recent years,DLBCL prognosis-related laboratory markers has progressed to more effectively predict patient prognosis and guides clinical treatment.This review summarizes the recent advances in laboratory markers in the prognosis of DLBCL.

Key words: Lymphoma, Large B-cell, Prognosis

CLC Number:

R733

LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2019.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2019/V33/I2/183

References

1 Sehn LH,Scott DW,Chhanabhai M,et al.Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP[J].J Clin Oncol,2011,29(11):1452-1457.
2 Bassig BA,Au WY,Mang O,et al.Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States,2001-2010[J].Cancer Epidemiol,2016,42:15-23.
3 Vaqué JP,Martínez N,Batlle-López A,et al.B-cell lymphoma mutations:improving diagnostics and enabling targeted therapies[J].Haematologica,2014,99(2):222.
4 Nakayama S,Yokote T,Akioka T,et al.Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma,not otherwise specified[J].Blood Adv,2017,1(8):486-493.
5 Wang J,Gao K,Lei W,et al.Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma:correlation with CD163 positive M2 type tumor-associated macrophages,not PD-1 positive tumor-infiltrating lymphocytes[J].Oncotarget,2016,8(3):5414-5425.
6 Melchardt T,Troppan K,Weiss L,et al.Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI[J].J Natl Compr Canc Netw,2015,13(12):1501-1508.
7 Shen M,Hu P,Donskov F,et al.Tumor-associated neutrophils as a new prognostic factor in cancer:a systematic review and Meta-analysis[J].PLoS One,2014,9(6):e98259.
8 Manfroi B,Mckee T,Mayol JF,et al.CXCL-8/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-Inducing ligand APRIL[J].Cancer Res,2017,77(5):1097-1107.
9 Schwaller J,Schneider P,Mhawech-Fauceglia P,et al.Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness[J].Blood,2007,109(1):331-338.
10 Porrata LF,Rsitow K,Inwards DJ,et al.Lymphopenia assessed during routine follow-up after immunochemotherapy(R-CHOP)is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma[J].Leukemia,2010,24(7):1343-1349.
11 Manfroi B,Moreaux J,Righini C,et al.Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients[J].Blood Cancer J,2018,8(7):66.
12 Mu S,Ai L,Fan F,et al.Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients:an updated dose-response meta-analysis[J].Cancer Cell Int,2018,18(1):119.
13 Marnell L,Mold C,Clos TWD.C-reactive protein:Ligands,receptors and role in inflammation[J].Clin Immunol,2005,117(2):104-111.
14 Woo HD,Kim K,Kim J.Association between preoperative C-reactive protein level and colorectal cancer survival:a meta-analysis[J].Cancer Causes Control,2015,26(11):1-10.
15 Luo Y,Fu SJ,She DL,et al.Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma:A systematic review and meta-analysis[J].Mol Clin Oncol,2015,3(4):924.
16 Huang Y,Feng JF,Liu JS.Prognostic role of serum C-reactive protein in esophageal cancer:a systematic review and meta-analysis[J].Ther Clin Risk Manag,2015,11:89-94.
17 Li N,Tian GW,Wang Y,et al.Prognostic role of the pretreatment C-reactive protein/albumin ratio in solid cancers:a Meta-analysis[J].Sci Rep,2017,7:41298.
18 Wang J,Zhou M,Wang X,et al.Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP[J].Clin Chim Acta,2016,459:150-154.
19 Qin W,Yuan Q,Wu J,et al.Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma:a meta-analysis[J].Leuk Lymphoma,2019,60(2):358-366.
20 Matsumoto K,Fujisawa S,Ando T,et al.Anemia associated with worse outcome in diffuse large B-cell lymphoma patients:a single-center retrospective study[J].Turk J Haematol,2018,35(3):181-184.
21 Hong J,Woo HS,Kim H,et al.Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy[J].Cancer Sci,2015,105(12):1569-1575.
22 Ochi Y,Kazuma Y,Hiramoto N,et al.Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma[J].Ann Hematol,2016,96(1):1-8.
23 Nakayama S,Matsuda M,Adachi T,et al.Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma,not otherwise specified in the R-CHOP era[J].Platelets,2018,26:1-9.
24 Bharadwaj S,Ginoya S,Tandon P,et al.Malnutrition:laboratory markers vs nutritional assessment[J].Gastroenterol Rep,2016,4(4):272-280.
25 Pfensig C,Dominik A,Borufka L,et al.A new application for albumin dialysis in extracorporeal organ support:characterization of a putative interaction between human albumin and proinflammatory cytokines IL‐6 and TNFα[J].Artif Organs,2016,40(4):397-402.
26 Seebacher V,Grimm C,Reinthaller A,et al.The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer[J].Eur J Obstet Gynecol Reprod Biol,2013,171(1):101-106.
27 Bairey O,Shacham-Abulafia A,Shpilberg O,et al.Serum albumin level at diagnosis of diffuse large B-cell lymphoma:an important simple prognostic factor[J].Hematol Oncol,2015,34(4):184-192.
28 Dalia S,Chavez J,Little B,et al.Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era[J].Ann Hematol,2014,93(8):1305-1312.
29 Adly L,Hill D,Sherman ME,et al.Serum concentrations of estrogens,sex hormone-binding globulin,and androgens and risk of breast cancer in postmenopausal women[J].Int J Cancer,2006,119(10):2402-2407.
30 Yao Y,Zhao M,Yuan D,et al.Elevated pretreatment serum globulin albumin ratio predicts poor prognosis for advanced non-small cell lung cancer patients[J].J Thorac Dis,2014,6(9):1261-1270.
31 Oki S,Toiyama Y,Okugawa Y,et al.Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients[J].Am J Surg,2017,214(5):891-898.
32 Toiyama Y,Yasuda H,Ohi M,et al.Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent[J].Am J Surg,2017,213(1):120-126.
33 Chen Z,Shao Y,Yao H,et al.Preoperative albumin to globulin ratio predicts survival in clear cell renal cell carcinoma patients[J].Oncotarget,2017,8(29):48291-48302.
34 Kim SH,Go SI,Seo J,et al.Prognostic impact of pretreatment albumin to globulin ratio in patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Leuk Res,2018,71:100-105.
35 Yue W,Liu B,Gao L,et al.The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma[J].Clin Chim Acta,2018,485:316-322.
36 Umino K,Fujiwara SI,Minakata D,et al.Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Leuk lymphoma,2018,6:1-8.
37 Dlouhy I,Filella X,Rovira J,et al.High serum levels of soluble interleukin-2 receptor(sIL2-R),interleukin-6(IL-6)and tumor necrosis factor alpha(TNF)are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma[J].Leuk Res,2017,59:20-25.
38 Umino K,Fujiwara SI,Ikeda T,et al.Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP[J].Hematology,2017,22(9):521-526.
39 Ma M,Zhao R,Yang X,et al.The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma[J].Exp Ther Med,2018,16(2):649-656.
40 Moreno MJ,Gallardo A,Novelli S,et al.CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis[J].PLoS One,2018,13(6):e0198789.
41 Wu X,Wang F,Li Y,et al.Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma[J].Oncol Lett,2018,15(6):9725-9734.
42 Ollila TA,Olszewski AJ.Extranodal diffuse large B cell lymphoma:molecular features,prognosis,and risk of central nervous system recurrence[J].Curr Treat Options Oncol,2018,19(8):38.
43 Ishikawa E,Tanaka T,Shimada K,et al.A prognostic model,including the EBV status of tumor cells,for primary gastric diffuse large B-cell lymphoma in the rituximab era[J].Cancer Med,2018,7(7):3510-3520.
44 Lee DY,Kang K,Jung H,et al.Extranodal involvement of diffuse large B-cell lymphoma in the head and neck:An indicator of good prognosis[J].Auris Nasus Larynx,2018[Epub ahead of print].
45 Kleinstern G,Maurer MJ,Liebow M,et al.History of autoimmune conditions and lymphoma prognosis[J].Blood Cancer J,2018,8(8):73.
46 Almansour MM,Alghamdi SA,Alsubaie MA,et al.Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma[J].Infect Agent Cancer,2018,13(1):18.
47 Witte H,Biersack H,Kopelke S,et al.The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma[J].Br J Haematol,2018[Epub ahead of print].
48 Tanimura A,Hirai R,Nakamura M,et al.The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse large B-cell lymphoma[J].Intern Med,2018[Epub ahead of print].

[1]	REN Fanghan, ZHU Tiancen, LI Yanxia, CHEN Lili, NA Jun, TIAN Yuanmeng, MU Huijuan. Analysis of the incidence and mortality of lymphoma in cancer registration areas of Liaoning Province from 2016 to 2020 and their changing trends [J]. Journal of Practical Oncology, 2025, 39(5): 388-392.
[2]	LI Xudong, LIU Tong. The single cell transcriptome sequencing reveals the role and prognostic value of PCLAF and ERO1A in the progression of breast cancer [J]. Journal of Practical Oncology, 2025, 39(5): 418-427.
[3]	LUO Danli, LI Fucheng, JIA Siyuan, DOU He, BA Yuling, GAO Tian, LI Zhaoting, XIAO Min. Effect of plasma atherosclerosis index on pathological complete response and prognosis of breast cancer patients treated with neoadjuvant chemotherapy [J]. Journal of Practical Oncology, 2025, 39(4): 316-323.
[4]	MA Ming, WANG Wanying, RUAN Yuli, LIU Chao, ZHANG Yanqiao, MA Zhigang. The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer [J]. Journal of Practical Oncology, 2025, 39(1): 39-48.
[5]	SUN Lijun, DONG Dawei. Classification and prognosis of ovarian cancer based on platinum resistance related genes [J]. Journal of Practical Oncology, 2024, 38(3): 184-191.
[6]	LIAO Jun, LI Chunfeng, XUE Yingwei, ZU Hongliang. Research progress of lactate dehydrogenase in the diagnosis and treatment of gastric cancer [J]. Journal of Practical Oncology, 2024, 38(3): 200-206.
[7]	YANG Peng, LUO Jinmei, LUO Ping, XIE Xiaobo. An immune score model based on immune cell infiltration predicts the effects of immunotherapy and prognosis of early gastric cancer [J]. Journal of Practical Oncology, 2024, 38(2): 121-130.
[8]	GAO Yan, YAO Mengcheng, LI Zhefeng, HAN Xiaoyang, YUE Wentao. Single cell sequencing data reveal the diagnostic and predictive value of DMKN in ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(6): 478-484.
[9]	DENG Jielian, ZHENG Wei, LI Kangjie, ZHANG Cong, ZHANG Yuan, XIE Biao, ZHONG Xiaoni. Construction of a prognostic risk prediction model in liver cancer for macrophage related genes based on single-cell RNA-seq and bulk RNA-seq data [J]. Journal of Practical Oncology, 2023, 37(5): 403-410.
[10]	YAN Chunhui, YU Ling, HE Wenyuan, CUI Wenzhi, WANG Zhuocai, YAN Guangning. Expression of Galectin-9 and CD8 in osteosarcoma and their correlation with clinical pathological characteristics and prognosis [J]. Journal of Practical Oncology, 2023, 37(4): 337-343.
[11]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[12]	XIANG Di, KOU Lina, DU Chunling, OU Xiaowen, CHEN Tiejun. Research progress on the relationship between systemic immune inflammatory index and prognosis of colorectal cancer [J]. Journal of Practical Oncology, 2023, 37(4): 377-382.
[13]	CUI Yongkang, YU Chengping, XU Haozhi, MA Xinyu, MA Yong, LI Linqiang. Effects of nutritional risk index in predicting postoperative complications and prognosis of patients with resectable hepatocellular carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 243-251.
[14]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[15]	LI Tong, LI Boya, QIN Ling. Research progress of XPO1 inhibitors in diffuse large B-cell lymphoma [J]. Journal of Practical Oncology, 2023, 37(2): 175-180.

Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments